Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Regenerative Collagen Scaffold for Breast Volume Restoration After Breast Cancer Excision

NCT: NCT07219316 · COMPLETED

NCT IDNCT07219316
StatusCOMPLETED
Start Date2025-10-15
Completion2026-02-25

Brief Summary

This clinical trial evaluates the safety and efficacy of High Purity Type I Collagen scaffold for breast volume restoration following breast-conserving surgery (BCS). The regenerative collagen matrix serves as a biocompatible scaffold promoting tissue ingrowth, neovascularization, and gradual remodeling, thereby improving cosmetic outcomes and patient quality of life after partial mastectomy.

Frequently Asked Questions

What is Regenerative Collagen Scaffold for Breast Volume Restoration After Breast Cancer Excision?

Regenerative Collagen Scaffold for Breast Volume Restoration After Breast Cancer Excision is a clinical trial registered under NCT07219316. Current status: COMPLETED.

What is the status of NCT07219316?

The current status of NCT07219316 (Regenerative Collagen Scaffold for Breast Volume Restoration After Breast Cancer Excision) is: COMPLETED.

When did Regenerative Collagen Scaffold for Breast Volume Restoration After Breast Cancer Excision start?

Regenerative Collagen Scaffold for Breast Volume Restoration After Breast Cancer Excision started on 2025-10-15.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑